Positron emission tomography/computed tomography in melanoma

Radiologic Clinics of North America

Volumn 51, Issue 5, 2013, Pages 865-879

  Bourgeois, Austin C ^a   Chang, Ted T ^a   Fish, Lindsay M ^a   Bradley, Yong C ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

CT; Cutaneous melanoma; Melanoma; PET

Indexed keywords

ALPHA INTERFERON; LACTATE DEHYDROGENASE; PROTEIN S100B; TUMOR MARKER;

ADRENAL GLAND; BONE METASTASIS; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE MARKER; GLUCOSE METABOLISM; HEART METASTASIS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; INTESTINE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MELANOMA METASTASIS; NUCLEAR MAGNETIC RESONANCE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE METASTASIS; SPLEEN METASTASIS; SURVIVAL RATE; THYROID CANCER; UROGENITAL SYSTEM; UVEA MELANOMA; VAGINA;

CT; CUTANEOUS MELANOMA; MELANOMA; PET;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883439937     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2013.06.004     Document Type: Review

References (70)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Choi E.A., Gershenwald J.E. Imaging studies in patients with melanoma. Surg Oncol Clin N Am 2007, 16(2):403-430.
3. Bevona C., Sober A.J. Melanoma incidence trends. Dermatol Clin 2002, 20(4):589-595. vii.
4. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. JClin Oncol 2001, 19(16):3635-3648.
5. Erdmann F., Tieulent J.L., Schüz J. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?. Int J Cancer 2013, 132(2):385-400.
6. Ho Shon I.A., Chung D.K., Saw R.P., et al. Imaging in cutaneous melanoma. Nucl Med Commun 2008, 29(10):847-876.
7. Lens M.B., Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004, 150(2):179-185.
8. Weiss M., Loprinzi C.L., Creagan E.T., et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995, 274(21):1703-1705.
9. Hofmann U., Szedlak M., Rittgen W., et al. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002, 87(2):151-157.
10. Aukema T.S., Olmos R.A., Korse C.M., et al. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 2010, 17(6):1657-1661.
11. Mohr P., Eggermont A.M., Hauschild A., et al. Stagingof cutaneous melanoma. Ann Oncol 2009, 20(Suppl 6):vi14-vi21.
12. Abbott R.A., Acland K.M., Harries M., et al. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. Melanoma Res 2011, 21(5):446-449.
13. Palmer S.R., Erickson L.A., Ichetovkin I., et al. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc 2011, 86(10):981-990.
14. Hoejberg L., Bastholt L., Johansen J.S., et al. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 2012, 22(4):287-293.
15. Mottaghy F.M., Sunderkötter C., Schubert R., et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging 2007, 34(9):1355-1364. Available at:. http://www.springerlink.com.prospero.mc.utmck.edu:2048/content/q61942k722480814/fulltext.pdf.
16. Strobel K., Skalsky J., Steinert H.C., et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 2007, 215(3):192-201.
17. Strobel K., Dummer R., Husarik D.B., et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007, 244(2):566-574.
18. Strobel K., Dummer R., Steinert H.C., et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging 2008, 35(10):1786-1795. Available at:. http://www.springerlink.com.prospero.mc.utmck.edu:2048/content/t04m526851381337/fulltext.pdf.
19. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. NEngl J Med 2006, 355(13):1307-1317.
20. Baldwin B.T., Cherpelis B.S., Sondak V., et al. Sentinel lymph node biopsy in melanoma: facts and controversies. Clin Dermatol 2010, 28(3):319-323.
21. El-Maraghi R.H., Kielar A.Z. PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. JAm Coll Radiol 2008, 5(8):924-931.
22. Iagaru A., Quon A., Johnson D., et al. 2-Deoxy-2-[F-18] fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 2007, 9(1):50-57.
23. Yancovitz M., Finelt N., Warycha M.A., et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007, 110(5):1107-1114.
24. Sabel M.S., Wong S.L. Review of evidence-based support for pretreatment imaging in melanoma. JNatl Compr Canc Netw 2009, 7(3):281-289.
25. Crippa F., Leutner M., Belli F., et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. JNucl Med 2000, 41(9):1491-1494.
26. Veit-Haibach P., Vogt F.M., Jablonka R., et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 2009, 36(6):910-918.
27. Singh B., Ezziddin S., Palmedo H., et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res 2008, 18(5):346-352.
28. Macapinlac H.A. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 2004, 10(4):262-270.
29. Dancey A.L., Mahon B.S., Rayatt S.S. Areview of diagnostic imaging in melanoma. Br J Plast Surg 2008, 61(11):1275-1283.
30. Tyler D.S., Onaitis M., Kherani A., et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000, 89(5):1019-1025.
31. Acland K.M., Healy C., Calonje E., et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. JClin Oncol 2001, 19(10):2674-2678.
32. Aukema T.S., Valdés Olmos R.A., Wouters W.M., et al. Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol 2010, 17(10):2773-2778.
33. Bronstein Y., Tummala S., Rohren E. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review. Clin Nucl Med 2011, 36(2):96.
34. Gulec S.A., Faries M.B., Lee C.C., et al. The role offluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003, 28(12):961-965.
35. Camargo Etchebehere E.C., Romanato J.S., Santos A.O., et al. Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun 2010, 31(11):925-930. Available at:. http://graphics.tx.ovid.com.prospero.mc.utmck.edu:2048/ovftpdfs/FPDDNCFBAALFLG00/fs046/ovft/live/gv023/00006231/00006231-201011000-00001.pdf.
36. Falk M.S., Truitt A.K., Coakley F.V., et al. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun 2007, 28(4):273-280. Available at:. http://graphics.tx.ovid.com.prospero.mc.utmck.edu:2048/ovftpdfs/FPDDNCFBAALFLG00/fs046/ovft/live/gv023/00006231/00006231-200704000-00008.pdf.
37. Buck A.K., Herrmann K., Stargardt T., et al. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. JNucl Med Technol 2010, 38(1):6-17.
38. Niederkohr R.D., Rosenberg J., Shabo G., et al. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun 2007, 28(9):688-695.
39. Bastiaannet E., Hoekstra H.J., Hoekstra O.S. Methods in molecular biology 2011, 123-139. Humana Press, Totowa (NJ). M.E. Juweid, O.S. Hoekstra (Eds.).
40. Querellou S., Keromnes N., Abgral R., et al. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma. Nucl Med Commun 2010, 31(9):766-772.
41. Pfluger T., Melzer H.I., Schneider V., et al. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging 2011, 38(5):822-831.
42. Gorospe L., Raman S., Echeveste J., et al. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun 2005, 26(8):671-687.
43. Dizendorf E.V., Treyer V., Van Schulthess G.K., et al. Application of oral contrast media in coregistered positron emission tomography-CT. Am J Roentgenol 2002, 179(2):477-481.
44. Otero H.J., Yap J.T., Patak M.A., et al. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol 2009, 193(2):326-332.
45. Prichard R.S., Hill A.D., Skehan S.J., et al. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002, 89(4):389-396.
46. Rohren E.M., Provenzale J.M., Barboriak D.P., et al. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy1. Radiology 2003, 226(1):181-187.
47. Kitajima K., Nakamoto Y., Okizuka H., et al. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 2008, 22(7):595-602.
48. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. JClin Oncol 2004, 22(14):2865-2872.
49. Hu D.N., Yu G.P., McCormick S.A., et al. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005, 140(4):612-617.
50. Kivelä T., Eskelin S., Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006, 46(1):133-149.
51. Schuster R., Bechrakis N.E., Stroux A., et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007, 13(4):1171-1178.
52. Servois V., Mariani P., Malhaire C., et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010, 36(2):189-194.
53. Patel P., Finger P.T. Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis. Am J Ophthalmol 2012, 153(4):661-668.
54. Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One 2012, 7(3):e32955.
55. Soelberg K.K., Bonnema S.J., Brix T., et al. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography. A systematic review. Thyroid 2012, [Epub ahead of print].
56. Kung B., Aftab S., Wood M., et al. Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J 2009, 88(1):E7.
57. Haerle S.K., Soyka M.B., Fischer D.R., et al. The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma. Eur Arch Otorhinolaryngol 2011, 269(1):127-133. Available at:. http://www.springerlink.com.prospero.mc.utmck.edu:2048/content/r560m4w3641t1r43/fulltext.pdf.
58. Cone L.A., Brochert A., Schulz K., et al. PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma. Clin Nucl Med 2007, 32(10):793.
59. Heusner T., Gölitz P., Hamami M., et al. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?. Eur J Radiol 2011, 78(3):430-435.
60. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? 2012;1-1.
61. Mayerhoefer M.E., Prosch H., Herold C.J., et al. Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?. Eur Radiol 2012, 22(11):2451-2457.
62. Cheng G., Newberg A. Metastatic melanoma causing complete atrioventricular block-the role of FDG PET/CT in diagnosis. Clin Imaging 2011, 35(4):312-314.
63. Karlen A.I., Clark J.J., Wong L.L. Two cases of partial hepatectomy for malignant melanoma. Hawaii J Med Public Health 2012, 71(4):92-96.
64. Quarles U.H., Zoon P., van Waes P., et al. Solitary splenic metastasis in a patient with a malignant melanoma diagnosed with F-18-FDG PET scanning. Clin Nucl Med 2005, 30(8):582.
65. Meehan C.P., Fuqua J.L., Reiner A.S., et al. Prognostic significance of adrenal gland morphology at CT in patients with three common malignancies. Br J Radiol 2012, 85(1014):807-812.
66. Ozcan Kara P., Kara T., Kara Gedik G., et al. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 2010, 32(2):106-112. Available at:. http://graphics.tx.ovid.com.prospero.mc.utmck.edu:2048/ovftpdfs/FPDDNCFBAALFLG00/fs046/ovft/live/gv023/00006231/00006231-201102000-00004.pdf.
67. Ozcan Kara P., Kara T., Kara Gedik G., et al. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 2011, 32(2):106-112.
68. Vaz P.S., Usurelu S., Monteiro A., et al. Small bowel metastatic of malignant melanoma: a rare cause of lower gastrointestinal bleeding. Acta Med Port 2011, 24(1):179-182.
69. Patti R., Cacciatori M., Guercio G., et al. Intestinal melanoma: a broad spectrum of clinical presentation. Int J Surg Case Rep 2012, 3(8):395-398.
70. Oudoux A., Rousseau T., Bridji B., et al. Interest of F-18 fluorodeoxyglucose positron emission tomography in the evaluation of vaginal malignant melanoma. Gynecol Oncol 2004, 95(3):765-768. Available at:. http://ac.els-cdn.com/S0090825804007024/1-s2.0-S0090825804007024-main.pdf?_tid=0a1b07fea10cd5c14ec65e7f780a94cd%26acdnat=1337983842_0594937df503e12badec82a7639b6e94.